InVivo Therapeutics Announces Enrollment of New Patient into the INSPIRE Study at Keck Hospital, University of Southern California
Mar 09, 2017 08:00:00 (ET)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 09, 2017--
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Keck Hospital of University of Southern California (USC). Patrick Hsieh, M.D., Principal Investigator at this site, performed the implantation approximately 82 hours after the injury occurred.
"The implantation of the Neuro-Spinal Scaffold went smoothly and the patient is recovering well," Dr. Hsieh said. "I have now implanted two patients, and it is rewarding to be able to give spinal cord injury patients hope with novel investigational products that were not available previously. I look forward to following and communicating the patient's progress."
Mark Perrin, InVivo's Chief Executive Officer and Chairman, said, "We are pleased to hear that the implantation procedure was a success and that the patient is doing well. We now have 12 patients enrolled and in follow up in INSPIRE, and this enrollment marks another significant step toward completing enrollment in the INSPIRE study."
AI
